CN114748492B - Medicine for treating atherosclerosis - Google Patents
Medicine for treating atherosclerosis Download PDFInfo
- Publication number
- CN114748492B CN114748492B CN202210522063.8A CN202210522063A CN114748492B CN 114748492 B CN114748492 B CN 114748492B CN 202210522063 A CN202210522063 A CN 202210522063A CN 114748492 B CN114748492 B CN 114748492B
- Authority
- CN
- China
- Prior art keywords
- trachelospermin
- ldl
- medicine
- caused
- human coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a medicine for treating atherosclerosis, and belongs to the technical field of medicine. The medicine comprises trachelospermin and a pharmaceutically acceptable carrier. The invention discovers that the trachelospermin can effectively reduce the decrease of the survival activity of the human coronary artery endothelial cells caused by ox-LDL, and can effectively reduce the increase of the protein expression of endothelial cell vascular adhesion molecules VCAM1 and intercellular adhesion molecules ICAM1 in the human coronary artery endothelial cells caused by ox-LDL. Meanwhile, the apoptosis increase caused by ox-LDL can be effectively reduced. Therefore, according to the invention, the trachelospermin is creatively used for preparing the medicine for treating atherosclerosis.
Description
Technical Field
The invention belongs to the technical field of medicine, and particularly relates to a medicament for treating atherosclerosis.
Background
In recent years, the number of cardiovascular disease patients in China is continuously increased, and at present, cardiovascular diseases become the leading threat factor of death of residents in China, urban and rural areas. Atherosclerosis is a common arterial vascular disease, which is caused by the fact that atheromatous plaque, which is composed of substances such as lipid, cholesterol, calcium and the like and surrounding cells, is deposited on the vascular wall to cause vascular stenosis, and meanwhile, the plaque can also rupture to form thrombus, so that other ischemic diseases are developed.
Vascular endothelial cells play an important role in atherosclerosis, and when damaged, they can cause monocyte aggregation to early atherosclerotic plaques by up-regulating the expression of endothelial cell vascular adhesion molecule VCAM1 and intercellular adhesion molecule ICAM 1. Meanwhile, the vascular endothelial cells can release various cell adhesion molecules to promote the adhesion of platelets, granulocytes and monocytes to the vascular endothelium, thereby promoting the occurrence and development of atherosclerosis. Therefore, the molecular mechanism of the occurrence and development of atherosclerosis is deeply studied by taking the vascular endothelial cells as the research direction, and the molecular mechanism has profound clinical significance for treating atherosclerosis.
The molecular formula of trachelospermin is C27H34O12, CAS number is 33464-71-0, and the prior art shows that trachelospermin can promote keratinocyte proliferation by stimulating ERK 1/2. However, there is no report on the use of trachelospermin in atherosclerosis.
Disclosure of Invention
The invention aims to provide a new application of trachelospermin in the treatment of atherosclerosis.
In order to realize the purpose, the invention provides the following technical scheme:
one is the application of trachelospermin in preparing atherosclerosis therapeutic medicine, and the CAS number of the trachelospermin is 33464-71-0.
Preferably, the trachelospermin reduces ox-LDL resulting in a decrease in survival activity of human coronary endothelial cells.
Preferably, the trachelospermin reduces the ox-LDL induced increase in protein expression of endothelial cell vascular adhesion molecule VCAM1 and intercellular adhesion molecule ICAM1 in human coronary endothelial cells.
Preferably, the trachelospermin reduces the up-regulation of mRNA expression of pro-apoptotic gene BAX caused by ox-LDL, and the trachelospermin up-regulates the down-regulation of mRNA expression of apoptosis-inhibiting gene Bcl-2 caused by ox-LDL.
Preferably, the concentration of the trachelospermin is greater than or equal to 5ug/ml.
The other is an atherosclerosis treatment drug which comprises trachelospermin and a pharmaceutically acceptable carrier.
Preferably, the pharmaceutically acceptable carrier is a diluent, carrier or excipient.
Preferably, the medicament dosage form is decoction, pill, powder, paste, pellet, electuary, oral liquid, capsule, tablet and injection.
And the third is the application of the trachelospermin in preparing the human coronary artery endothelial cell survival activity accelerant, and the trachelospermin reduces the decrease of the human coronary artery endothelial cell survival activity caused by ox-LDL.
And fourthly, the application of the trachelospermin in preparing the adhesion molecule protein expression inhibitor in the human coronary artery endothelial cells, wherein the trachelospermin reduces the increase of the protein expression of endothelial cell vascular adhesion molecules VCAM1 and intercellular adhesion molecules ICAM1 in the human coronary artery endothelial cells caused by ox-LDL.
Fifthly, the application of the trachelospermin in preparing the human coronary artery endothelial cell apoptosis inhibitor, the trachelospermin reduces the up-regulation of the mRNA expression of the pro-apoptosis gene BAX caused by ox-LDL, and the up-regulation of the trachelospermin reduces the mRNA expression of the apoptosis-inhibiting gene Bcl-2 caused by ox-LDL.
Preferably, the concentration of the trachelospermin is greater than or equal to 5ug/ml.
The invention has the beneficial effects that:
the invention proves that the survival activity of endothelial cells of human coronary arteries can be effectively reduced due to ox-LDL after the pretreatment by using the trachelospermin;
secondly, the invention proves that the protein expression of endothelial cell vascular adhesion molecules VCAM1 and intercellular adhesion molecules ICAM1 in human coronary artery endothelial cells caused by ox-LDL can be effectively reduced after the pretreatment by using the trachelospermin;
in addition, the present invention demonstrates that the mRNA expression of pro-apoptotic gene BAX caused by ox-LDL can be decreased up-regulated by using the pre-treatment with trachelospermin, which down-regulates the mRNA expression of pro-apoptotic gene Bcl-2 caused by ox-LDL to decrease apoptosis.
Therefore, the trachelospermin can be used for preparing the medicine for treating atherosclerosis.
Drawings
FIG. 1 the effect of trachelospermin on ox-LDL induced protein expression of the endothelial cell vascular adhesion molecule VCAM1 and the intercellular adhesion molecule ICAM 1;
FIG. 2 effect of trachelospermin on mRNA expression of BAX by ox-LDL;
FIG. 3 the effect of trachelospermin on ox-LDL induced mRNA expression of BCL-2.
Detailed Description
The examples are provided for better illustration of the invention, but the invention is not limited to the examples. Therefore, those skilled in the art can make insubstantial modifications and adaptations to the embodiments described above without departing from the scope of the present invention.
Example 1
Role of tracheloside in inhibition of HCAEC cell (human coronary artery endothelial cell) growth by oxidation of low density lipoprotein
(1) Collecting HCAEC cells which have good growth state and have the growth density of 80% into a centrifuge tube according to a cell passage method, and re-suspending the cells by using a complete culture medium;
(2) Counting 10ul of cell suspension with a hemocytometer, and diluting the cell suspension to a density of 3X 10 based on the cell termination results 4 number/ML;
(3) Adding 100ul of suspension into each well of a 96-well plate, gently shaking and uniformly mixing, and then adding PBS into peripheral wells of inoculated cells so as to prevent edge effect caused by water evaporation;
(4) Removing the culture medium in the 96-well plate after 24h, adding 100ul of serum-free culture medium containing 0.1% bovine serum albumin into each well to ensure that the cells are in a starvation state and all the cell states are adjusted to be consistent, and removing the culture medium after the cells are subjected to starvation treatment for 6 h;
(5) Grouping as follows: the control group was cultured in complete medium, experiment group a was treated with 0ug/ml of trachelospermin for 24 hours and then cultured in complete medium containing 100mg/L of ox-LDL for 24 hours, experiment group b was treated with 5ug/ml of trachelospermin for 24 hours and then cultured in complete medium containing 100mg/L of ox-LDL for 24 hours, and experiment group c was treated with 10ug/ml of trachelospermin for 24 hours and then cultured in complete medium containing 100mg/L of ox-LDL for 24 hours; experimental group d was treated with 25ug/ml of trachelospermin for 24 hours, and then cultured in complete medium containing 100mg/L of ox-LDL for 24 hours; experimental group e was treated with 50ug/ml of trachelospermin for 24 hours, and cultured using complete medium containing 100mg/L of ox-LDL, each group being provided with 3 duplicate wells.
(6) Adding 10ul of CCK-8 detection reagent into 100ul of culture medium according to a system of 10.
Example 2
(1) Inoculating HCAEC cells into a 6-well culture substrate, and culturing a control group by using a complete culture medium when the cell density reaches 85%; experiment group a was treated with 0ug/ml of trachelospermin for 24 hours, and cultured in complete medium containing 100mg/L of ox-LDL for 24 hours; after the experiment group b was treated with 25ug/ml of trachelospermin for 24 hours, it was cultured in complete medium containing 100mg/L of ox-LDL for 24 hours, each group having 3 replicate wells;
(2) After the treatment, the culture medium was removed, the cells were washed with PBS, 100ul RIPA cell lysate was added to each well, and the cells were lysed for 30min;
(3) After the cracking is finished, transferring the cracking solution into a centrifuge tube, then placing the centrifuge tube into a low-temperature high-speed centrifuge, centrifuging for 18min at 4 ℃ at 12000g/min, taking out the centrifuge tube, and transferring the supernatant into a new centrifuge tube;
(4) Taking 2ul of supernatant to perform protein concentration detection by referring to the instruction of the BCA protein detection kit;
(5) Adding a sample buffer solution according to the detected protein concentration, boiling for 5min to obtain a protein sample,
Example 3
(1) Putting the prepared gel into a vertical electrophoresis apparatus, and adding an electrophoresis buffer solution into the designated scale mark of an electrophoresis tank;
(2) Adding 20ug of protein sample into the gel hole, and adding a protein Marker into the first gel hole;
(3) Correctly installing an electrophoresis apparatus according to the sequence of the anode and the cathode, adjusting the electrophoresis condition of the concentrated gel to 80V 30min, then adjusting the voltage to 120V until the electrophoresis strip reaches the lowest part, and stopping electrophoresis;
(4) Sequentially putting a PVDF membrane into methanol, ultrapure water and a membrane transferring buffer solution for soaking, simultaneously soaking a sponge in the membrane transferring buffer solution for 30min, taking out gel after electrophoresis is finished, putting the gel, the sponge, the PVDF membrane, the gel and the sponge in a semi-dry membrane transferring instrument in order, and transferring the membrane 250mA 90min;
(5) After the membrane transfer is finished, putting the PVDF membrane into 5 percent skim milk powder for sealing for 1h, and eluting for 3 multiplied by 5min by TBST solution;
(6) Putting the membrane into primary-antibody diluent containing 2% skimmed milk powder, standing overnight at 4 deg.C, and eluting in TBST solution for 3 × 5min;
(7) Putting the membrane into a secondary antibody diluent containing 5% skimmed milk powder, eluting for 3 x 5min in a TBST solution at room temperature for 1h;
(8) And dropwise adding the ECL developing solution on the PVDF membrane for reaction for 1min, and then placing the PVDF membrane in a gel imager for observation.
Example 4
(1) Inoculating HCAEC cells into a 6-well culture substrate, and culturing a control group by using a complete culture medium when the cell density reaches 85%; experimental group a was treated with 0ug/ml of trachelospermin for 24 hours, and then cultured in complete medium containing 100mg/L of ox-LDL for 24 hours; after the experiment group b is treated by 25ug/ml of trachelospermin for 24h, the experiment group b is cultured by using a complete culture medium containing 100mg/L of ox-LDL for 24h, and each group is provided with 3 repeated holes;
(2) Removing the culture medium, adding 1ml of Trizol, blowing and beating the cells by using a pipette, standing at room temperature for 5min, and sucking the mixed solution into a centrifuge tube;
(3) Placing in a low-temperature centrifuge, centrifuging at 12000rpm for 5min, sucking supernatant, and removing precipitate;
(4) Adding 0.2mL of chloroform, shaking and uniformly mixing, and standing at room temperature for 15 minutes;
(5) Then placing the centrifuge tube in a centrifuge, and centrifuging for 15min at 4 ℃ and 12000 rpm;
(6) Transferring the supernatant into a new centrifuge tube, adding equal-volume precooled isopropanol, uniformly mixing, and standing for 8 minutes on ice;
(7) Placing the centrifugal tube in a centrifugal machine again, centrifuging for 10 minutes at 4 ℃ and 12000rpm, removing supernatant, and keeping precipitate;
(8) Adding 1ml of 75% ethanol into the precipitate, shaking and centrifuging to suspend the precipitate;
(9) Centrifuging at 8000rpm at 4 deg.C for 5min, and carefully removing supernatant with a pipette;
(10) The RNA was dried by standing at room temperature for 10 minutes, and then the precipitate was dissolved with 50. Mu.L of DEPC water;
(11) The purity and concentration of total RNA in the tissue was determined using a micro uv spectrophotometer.
Example 5
(1) Removal of genomic DNA
Reaction reagents: 2.0. Mu.L of 5 Xg DNA Eraser Buffer,
gDNA Eraser 1.0μL，
Total RNA 1.0μg，
RNase Free dH2O up to 10.0μL。
the reaction conditions are as follows: 42 ℃ for 2 minutes, 4 ℃.
(2) Reverse transcription reaction
Reaction reagents: 10.0. Mu.L of the reaction solution in the step (1),
PrimeScript RT Enzyme Mix I 1.0μL，
RT Primer Mix 1.0 μL，
5×PrimeScript Buffer 2 4.0 μL，
RNase Free dH2O 4.0 μL。
reaction conditions are as follows: 15 minutes at 37 ℃,5 seconds at 85 ℃ and 4 ℃.
(3) Fluorescent quantitative PCR detection
SYBR Green Premix Ex Taq (2X) 10.0. Mu.l,
an upstream primer: 0.4 mu L of the suspension liquid is prepared,
a downstream primer: 0.4 mu L of the suspension liquid is prepared,
the cDNA template was 2.0. Mu.L,
ddH2O 7.2μL。
reaction conditions are as follows: 10min at 95 ℃;95 ℃ 15s,59 ℃ 60s 40 cycles; 5min at 75 ℃.
The primer sequences are as follows:
BCL-2
an upstream primer: 5-GACTTCGCCGAGATGTCCAG-3;
a downstream primer: 5-CGGTGCTTGGCAATTAGTGG-3;
BAX
an upstream primer: 5-ATGGAGCTGCAGGAGGATTCG-3;
a downstream primer: 5-AATGTCCAGCCCATGATGGT-3;
β-actin
an upstream primer: 5-catgagaagagattatgaacag-3;
a downstream primer: 5-AGTCCTTCCACGATACCAAA-3;
the experimental results of the invention are as follows:
experimental results for example 1:
TABLE 1 role of tracheloside in HCAEC cell growth inhibition by oxidation of low density lipoproteins
| Experimental groups | Growth inhibition rate |
| Experimental group a | 30.88±1.26 |
| Experimental group b | 22.31±1.54 ** |
| Experimental group c | 17.72±1.55 *** |
| Experimental group d | 10.15±0.82 *** |
| Experimental group e | 14.06±0.98 *** |
As can be seen from the above table, the growth of HCAEC cells can be inhibited after treatment with ox-LDL, while the growth inhibition of HCAEC cells by ox-LDL can be effectively reduced after the HCAEC cells are pretreated with tracheloside, and the difference is statistically significant. Furthermore, it can be seen that example d works best, so the present invention has 25ug/ml of trachelospermin as the optimum treatment concentration.
Experimental results of example 3
As can be seen from FIG. 1, the treatment with ox-LDL effectively promoted the protein expression of ICAM-1 and VCAM-1 in HCAEC cells, indicating that the treatment with ox-LDL increased the expression of cell adhesion factors, thereby promoting the adhesion of monocytes and lymphocytes;
after the pretreatment with 25ug/ml of the trachelospermin, compared with the experimental group a, the levels of protein expression of ICAM-1 and VCAM-1 were significantly reduced, which indicates that the cellular adhesion factor expression caused by ox-LDL can be effectively reduced after the pretreatment with the trachelospermin, thereby effectively preventing the occurrence of atherosclerosis.
Experimental results of example 5
As can be seen from fig. 2, the mRNA expression of the pro-apoptotic gene BAX in HCAEC cells was effectively promoted after treatment with ox-LDL (1.87 ± 0.22, the difference was statistically significant), whereas the mRNA expression level of BAX in experimental group b was decreased after pretreatment with 25ug/ml of trachelospermin (1.31 ± 0.17, the difference was statistically significant) compared to experimental group a;
as can be seen from FIG. 3, the mRNA expression of the apoptosis-inhibiting gene Bcl-2 in HCAEC cells was effectively reduced (0.51. + -. 0.06) after treatment with ox-LDL, whereas the level of mRNA expression of Bcl-2 in experimental group b was up-regulated (0.86. + -. 0.07) compared to experimental group a after pretreatment with 25ug/ml of trachelospermin;
from the above results, it can be seen that the pretreatment with 25ug/ml of trachelospermin can effectively reduce the apoptosis caused by ox-LDL.
Claims (5)
1. The application of the trachelospermin in preparing the medicine for treating atherosclerosis is characterized in that the CAS number of the trachelospermin is 33464-71-0.
2. The use according to claim 1, wherein said trachelospermin reduces ox-LDL resulting in a decrease in survival activity of human coronary endothelial cells.
3. The use according to claim 1, wherein said trachelospermin reduces ox-LDL resulting in increased protein expression of endothelial cell vascular adhesion molecule VCAM1 and intercellular adhesion molecule ICAM1 in human coronary endothelial cells.
4. The use according to claim 1, wherein said trachelospermin reduces the up-regulation of the mRNA expression of the pro-apoptotic gene BAX caused by ox-LDL, and wherein said trachelospermin up-regulation of the mRNA expression of the pro-apoptotic gene Bcl-2 caused by ox-LDL is down-regulated.
5. The use according to claim 1, wherein the concentration of said trachelospermin used is 5ug/ml or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210522063.8A CN114748492B (en) | 2022-05-13 | 2022-05-13 | Medicine for treating atherosclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210522063.8A CN114748492B (en) | 2022-05-13 | 2022-05-13 | Medicine for treating atherosclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114748492A CN114748492A (en) | 2022-07-15 |
| CN114748492B true CN114748492B (en) | 2023-03-10 |
Family
ID=82334757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210522063.8A Active CN114748492B (en) | 2022-05-13 | 2022-05-13 | Medicine for treating atherosclerosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114748492B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850979A (en) * | 2006-03-07 | 2006-10-25 | 谭兴起 | Chinese starjasmine stem lignin aglycone total extract and its extracting process |
| CN1919856A (en) * | 2005-08-26 | 2007-02-28 | 中国人民解放军军事医学科学院毒物药物研究所 | Caulis trachelospermi total lignans extractive, extraction method and medicine use of the extractive and active constituent thereof |
| CN103083312A (en) * | 2013-01-23 | 2013-05-08 | 中国人民解放军第二军医大学 | Applications of Chinese starjasmine stem aglycon, burdock aglycon and Chinese starjasmine stem glucoside as dibenzyl butyrolactone compounds to preparation of medicaments for treating hepatitis viruses |
| CN107602642A (en) * | 2017-10-13 | 2018-01-19 | 陕西嘉禾药业有限公司 | A kind of method of the extraction purification tracheloside from kardiseed |
| KR101899818B1 (en) * | 2017-12-06 | 2018-09-20 | 경희대학교 산학협력단 | A composition for wound healing comprising tracheloside |
| CN113759038A (en) * | 2021-08-26 | 2021-12-07 | 北京康仁堂药业有限公司 | Trachelospermi caulis characteristic map, construction method and quality control method thereof, Trachelospermi caulis formula granules and preparation method thereof |
-
2022
- 2022-05-13 CN CN202210522063.8A patent/CN114748492B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919856A (en) * | 2005-08-26 | 2007-02-28 | 中国人民解放军军事医学科学院毒物药物研究所 | Caulis trachelospermi total lignans extractive, extraction method and medicine use of the extractive and active constituent thereof |
| CN1850979A (en) * | 2006-03-07 | 2006-10-25 | 谭兴起 | Chinese starjasmine stem lignin aglycone total extract and its extracting process |
| CN103083312A (en) * | 2013-01-23 | 2013-05-08 | 中国人民解放军第二军医大学 | Applications of Chinese starjasmine stem aglycon, burdock aglycon and Chinese starjasmine stem glucoside as dibenzyl butyrolactone compounds to preparation of medicaments for treating hepatitis viruses |
| CN107602642A (en) * | 2017-10-13 | 2018-01-19 | 陕西嘉禾药业有限公司 | A kind of method of the extraction purification tracheloside from kardiseed |
| KR101899818B1 (en) * | 2017-12-06 | 2018-09-20 | 경희대학교 산학협력단 | A composition for wound healing comprising tracheloside |
| CN113759038A (en) * | 2021-08-26 | 2021-12-07 | 北京康仁堂药业有限公司 | Trachelospermi caulis characteristic map, construction method and quality control method thereof, Trachelospermi caulis formula granules and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 环氧化酶-2与动脉粥样硬化;甄琴等;《实用心脑肺血管病杂志》;20060325;第14卷(第3期);第522-524页 * |
| 络石藤中COX-2抑制成分的筛选及其对炎性痛和癫痫治疗作用的研究;姬晓彤;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20220315(第3期);E057-355 * |
| 络石藤中的木脂素类成分及其生物活性;西部三省等;《中国民族民间医药》;20010205(第48期);第1-2页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114748492A (en) | 2022-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Exosomes of stem cells from human exfoliated deciduous teeth as an anti-inflammatory agent in temporomandibular joint chondrocytes via miR-100-5p/mTOR | |
| CN108546702B (en) | siRNA of targeting long-chain non-coding RNA DDX11-AS1 and application thereof in liver cancer treatment | |
| CN104306993B (en) | Application of the circulation miR 505 in hypertension early diagnosis and target organ earlier damage forewarning function | |
| CN110804613B (en) | Application of siRNA for targeted inhibition of lncRNA-00861 gene expression in liver cancer treatment | |
| CN108179194B (en) | Tumor molecular marker circBIRC6, and inhibitor and application thereof | |
| CN103642927A (en) | Reagent for detecting autophagy signal pathway, PCR (polymerase chain reaction) detection method and application of reagent | |
| CN109674809B (en) | Composition containing miR-124-3P and application thereof in medicine for inducing neuron formation | |
| CN112852818A (en) | Circular RNA hsa _ circ _0001550 and application thereof | |
| CN111254146B (en) | Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer | |
| Liu et al. | Enhanced Effect of IL-1β-Activated Adipose-Derived MSCs (ADMSCs) on Repair of Intestinal Ischemia-Reperfusion Injury via COX-2-PGE 2 Signaling | |
| CN111249290B (en) | Application of gypenoside XLIX in preparation of medicine for improving liver fat metabolism | |
| CN114748492B (en) | Medicine for treating atherosclerosis | |
| CN111671903A (en) | Application of miR-10a mediated tumor-associated fibroblast to inhibition of liver metastasis of colon cancer | |
| Rahbarghazi et al. | c-kit+ cells offer hopes in ameliorating asthmatic pathologies via regulation of miRNA-133 and miRNA-126 | |
| CN111647660B (en) | Application of Linc01559 in diagnosis and treatment of gastric cancer | |
| Gerhard et al. | Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis | |
| CN113069548B (en) | Reagent for cardiac revascularization | |
| CN113768947B (en) | Application of gene inhibitor in preparation of ischemic heart disease treatment medicine | |
| CN112439068A (en) | Use of snord78 molecule in diagnosis and/or treatment of esophageal squamous carcinoma | |
| Geng et al. | Luteolin Inhibited the Self-Renewal and Altered the Polarization of Primary Alveolar Macrophages | |
| Lin et al. | Stimulatory influences of far infrared therapy on the transcriptome and genetic networks of endothelial progenitor cells receiving high glucose treatment | |
| CN104027820B (en) | A kind of applications of miRNA in treating or diagnosing hyperlipidemia and arteriosclerosis disease | |
| CN114807348B (en) | Application of long-chain non-coding RNA LRA-1 and interfering RNA thereof in treatment of atherosclerosis | |
| CN108796070B (en) | Application of miR-125a-3p in preparation of cardiovascular disease diagnosis kit | |
| CN114452280B (en) | Application of atractylone in preparation of glioma treatment drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |